Eva Muñoz‐Couselo

4.8k citations

89 papers · 2.1k indexed · 2 hit papers · h-index 20

Impact in

Oncology top 2%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Cancer Cells and Metastasis
- HER2/EGFR in Cancer Research
Cancer Research top 5%
- Cancer Genomics and Diagnostics

Papers in ⓘ

Oncology 74
- Cancer Immunotherapy and Biomarkers 49
- CAR-T cell therapy research 23
- Cutaneous Melanoma Detection and Management 15
- HER2/EGFR in Cancer Research 11
Cancer Research 19
- Cancer Genomics and Diagnostics 10
- Breast Cancer Treatment Studies 7

Co-authors: Javier Cortés (24 shared papers)José Manuel Pérez-García (13 shared papers)Carolina Ortiz (10 shared papers)Seock‐Ah Im (6 shared papers)Vassiliki Karantza (7 shared papers)Rebecca Dent (7 shared papers)Peter Schmid (5 shared papers)Esther Zamora (7 shared papers)
Journals: Journal of Clinical Oncology (21 papers)Annals of Oncology (10 papers)Clinical & Translational Oncology (7 papers)OncoTargets and Therapy (3 papers)Cancer Research (3 papers)
Partner nations: Spain United States France

In The Last Decade

Eva Muñoz‐Couselo

78 papers receiving 2.0k citations

Hit Papers

align trajectories log scale

Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial 2021 · 330 citations

Peers

Countries citing papers authored by Eva Muñoz‐Couselo

Since Specialization

Citations

This map shows the geographic impact of Eva Muñoz‐Couselo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eva Muñoz‐Couselo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eva Muñoz‐Couselo more than expected).

Fields of papers citing papers by Eva Muñoz‐Couselo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eva Muñoz‐Couselo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eva Muñoz‐Couselo. The network helps show where Eva Muñoz‐Couselo may publish in the future.

Co-authors

The 25 scholars most cited alongside Eva Muñoz‐Couselo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Eva Muñoz‐Couselo Line = papers co-authored together Eva Muñoz‐Couselo links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 89 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial The Lancet Oncology ·Eric P. Winer, Oleg Lipatov, Seock‐Ah Im, Anthony Gonçalvès, Eva Muñoz‐Couselo, Keun Seok Lee, Peter Schmid, Kenji Tamura, Laura Testa, Isabell Witzel, Shoichiro Ohtani, Nicholas C. Turner, Stefania Zambelli, Nadia Harbeck, Fabrice André, Rebecca Dent, Xuan Zhou, Vassiliki Karantza, Jaime Mejia, Javier Cortés Hit paper breakdown →	2021	330
2	Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study Annals of Oncology ·Peter Schmid, Roberto Salgado, Y.H. Park, Eva Muñoz‐Couselo, S.B. Kim, Joohyuk Sohn, Seock‐Ah Im, Theodoros Foukakis, Sherko Küemmel, Rebecca Dent, Lei Yin, A. Wang, Konstantinos Tryfonidis, Vassiliki Karantza, Javier Cortés, Sherene Loi Hit paper breakdown →	2020	279
3	Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1/PD-L1 therapy. Journal of Clinical Oncology ·Paolo A. Ascierto, Ignacio Melero, Shailender Bhatia, Petri Bono, Rachel E. Sanborn, Evan J. Lipson, Margaret K. Callahan, Thomas F. Gajewski, Carlos Gomez‐Roca, F. Stephen Hodi, Giuseppe Curigliano, Marta Nyakas, Matthias Preusser, Yoshinobu Koguchi, Matthew Maurer, Raphael Clynes, Priyam Mitra, Satyendra Suryawanshi, Eva Muñoz‐Couselo	2017	191
4	<em>NRAS</em>-mutant melanoma: current challenges and future prospect OncoTargets and Therapy ·Eva Muñoz‐Couselo, Esther Zamora, Carolina Ortiz, Jesús Soberino-García, José Manuel Pérez-García	2017	118
5	Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors Annals of Oncology ·César Serrano, Javier Cortés, Leticia De Mattos‐Arruda, Meritxell Bellet, P. Gómez, Cristina Saura, José Pérez, María Vidal, Eva Muñoz‐Couselo, María-Josep Carreras, Gessamí Sánchez-Ollé, Josep Tabernero, José Baselga, Serena Di Cosimo	2011	112
6	A slow-cycling LGR5 tumour population mediates basal cell carcinoma relapse after therapy Nature ·Adriana Sánchez‐Danés, Jean‐Christophe Larsimont, Mélanie Liagre, Eva Muñoz‐Couselo, Gaëlle Lapouge, Audrey Brisebarre, Christine Dubois, Mariano Suppa, Vijayakumar Sukumaran, V. del Mármol, Josep Tabernero, Cédric Blanpain	2018	97
7	Targeting FGFR pathway in breast cancer The Breast ·José Manuel Pérez-García, Eva Muñoz‐Couselo, Jesús Soberino, Fabricio Racca, Javier Cortés	2017	83
8	Pembrolizumab (pembro) + chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): Preliminary results from KEYNOTE-173. Journal of Clinical Oncology ·Peter Schmid, Yeon Hee Park, Eva Muñoz‐Couselo, Sung‐Bae Kim, Joohyuk Sohn, Seock‐Ah Im, Esther Holgado, Yang Wang, Thao P. Dang, Gursel Aktan, Javier Cortés	2017	68
9	BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors Melanoma Research ·María González‐Cao, Clara Mayo‐de‐las‐Casas, Miguel Ángel Molina‐Vila, Leticia De Mattos‐Arruda, Eva Muñoz‐Couselo, José Luís Zamora Manzano, Javier Cortés, José Pablo Berros, Ana Drozdowskyj, Miguel F. Sanmamed, Álvaro González, Carlos Álvarez-Fernández, Santiago Viteri, Niki Karachaliou, Salvador Martín‐Algarra, Jordi Bertrán-Alamillo, Núria Jordana‐Ariza, Rafael Rosell	2015	65
10	Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab Clinical Cancer Research ·Omid Hamid, Luciana Molinero, Christopher R. Bolen, Jeffrey A. Sosman, Eva Muñoz‐Couselo, Harriet M. Kluger, David F. McDermott, John D. Powderly, Indrani Sarkar, Marcus Ballinger, Marcella Fassò, Carol O’Hear, Daniel S. Chen, Priti S. Hegde, F. Stephen Hodi	2019	58
11	Immune‐related hepatitis related to checkpoint inhibitors: Clinical and prognostic factors Liver International ·Mar Riveiro‐Barciela, Ana Barreira‐Díaz, Judit Vidal‐González, Eva Muñoz‐Couselo, Fernando Martínez‐Valle, L Viladomiu, Beatriz Mínguez, Carolina Ortiz, Lluı́s Castells, Rafael Esteban, Marı́a Buti	2020	51
12	Association of tumor mutational burden (TMB) and clinical outcomes with pembrolizumab (pembro) versus chemotherapy (chemo) in patients with metastatic triple-negative breast cancer (mTNBC) from KEYNOTE-119. Journal of Clinical Oncology ·Eric P. Winer, Oleg Lipatov, Seock‐Ah Im, Anthony Gonçalvès, Eva Muñoz‐Couselo, Keun Seok Lee, Peter Schmid, Laura Testa, Isabell Witzel, Shoichiro Ohtani, Jared Lunceford, Vassiliki Karantza, Jaime Mejia, Răzvan Cristescu, Deepti Aurora-Garg, Petar Jelinic, Lingkang Huang, Javier Cortés	2020	48
13	Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies The Journal of Experimental Medicine ·Azad Saei, Marta Palafox, Touati Benoukraf, Nishi Kumari, Patrick Jaynes, Prasanna Vasudevan Iyengar, Eva Muñoz‐Couselo, Paolo Nucíforo, Javier Cortés, Christopher Nötzel, Nesaretnam Barr Kumarakulasinghe, John Lalith Charles Richard, Zul Fazreen Bin Adam Isa, Brendan Pang, Marta Guzmán, Siqin Zhou, Henry Yang, Wai Leong Tam, Violeta Serra, Pieter J.A. Eichhorn	2018	44
14	Retreatment With Immune Checkpoint Inhibitors After a Severe Immune-Related Hepatitis: Results From a Prospective Multicenter Study Clinical Gastroenterology and Hepatology ·Mar Riveiro‐Barciela, Ana Barreira‐Díaz, Ana Callejo, Eva Muñoz‐Couselo, Nely Díaz‐Mejía, Álvaro Díaz‐González, María‐Carlota Londoño, María-Teresa Salcedo, Marı́a Buti	2022	34
15	Incidence and clinical implications of a new definition of hyperprogression (HPD) with immune checkpoint inhibitors (ICIs) in patients treated in phase 1 (Ph1) trials. Journal of Clinical Oncology ·Ignacio Matos, Juan Martín-Liberal, Cinta Hierro, María Ochoa de Olza, Cristina Viaplana, Marinha Costa, Eudald Felip-Falg’s, Gemma Mur-Bonet, María Vieito, Irene Braña, Analía Azaro, Coral Perez-Gago, Víctor Rodríguez-Freixinós, Guillem Argilés, Mafalda Oliveira, Enriqueta Felip, Eva Muñoz‐Couselo, Josep Tabernero, Rodrigo Dienstmann, Elena Garralda	2018	29
16	A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy Clinical Cancer Research ·Sarah A. Weiss, Mario Sznol, Montaser Shaheen, Miguel‐Ángel Berciano‐Guerrero, Eva Muñoz‐Couselo, Delvys Rodríguez‐Abreu, Valentina Boni, Lynn M. Schuchter, María González‐Cao, Ana Arance, Wei Wei, Apar Kishor Ganti, Ralph J. Hauke, Alfonso Berrocal, Nicholas Iannotti, Frank J. Hsu, Harriet M. Kluger	2023	28
17	STK11 (LKB1) missense somatic mutant isoforms promote tumor growth, motility and inflammation Communications Biology ·Paula Granado‐Martínez, Sara García-Ortega, Elena González‐Sánchez, Kimberley McGrail, Rafael Selgas, Judit Grueso, R. Sánchez Gil, Neia Naldaiz‐Gastesi, Ana Carolina Rhodes, Javier Hernández‐Losa, Berta Ferrer-Rosell, Françesc Canals, Josep Villanueva, Olga Méndez, Sergio Espinosa-Gil, José M. Lizcano, Eva Muñoz‐Couselo, Vicenç García-Patos, Juan A. Recio	2020	27
18	Current Perspectives and Novel Strategies of NRAS-Mutant Melanoma OncoTargets and Therapy ·Alejandro García‐Álvarez, Carolina Ortiz, Eva Muñoz‐Couselo	2021	26
19	HER2 and hormone receptor-positive breast cancer—blocking the right target Nature Reviews Clinical Oncology ·Javier Cortés, Cristina Saura, Meritxell Bellet, Eva Muñoz‐Couselo, Natalia Ramírez-Merino, Virginia Calvo, José Pérez, María Vidal	2010	22
20	Recent advances in the treatment of melanoma with BRAF and MEK inhibitors. PubMed ·Eva Muñoz‐Couselo, Jesús Soberino García, José Manuel Pérez-García, Vanesa Ortega Cebrián, J. Cortés Castán	2015	22

About Eva Muñoz‐Couselo

Eva Muñoz‐Couselo is a scholar working on Oncology, Cancer Research, Immunology, Molecular Biology and Pulmonary and Respiratory Medicine, having authored 89 papers that have together received 2.1k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (49 papers), Melanoma and MAPK Pathways (23 papers), CAR-T cell therapy research (23 papers), Immunotherapy and Immune Responses (16 papers), Cutaneous Melanoma Detection and Management (15 papers), HER2/EGFR in Cancer Research (11 papers), Cancer Genomics and Diagnostics (10 papers) and Breast Cancer Treatment Studies (7 papers). The work is most often cited by research in Oncology (1.6k citations), Cancer Research (446 citations), Immunology (574 citations), Pulmonary and Respiratory Medicine (418 citations) and Molecular Biology (598 citations). Eva Muñoz‐Couselo has collaborated with scholars based in Spain, United States and France. Frequent co-authors include Javier Cortés, José Manuel Pérez-García, Carolina Ortiz, Seock‐Ah Im, Vassiliki Karantza, Rebecca Dent, Peter Schmid, Esther Zamora, Joohyuk Sohn and Laura Testa. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Clinical & Translational Oncology, OncoTargets and Therapy and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact